X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-18 | DYN | Incerti Carlo | Dir | S - Sale+OE | $28.73 | -16,500 | 0 | -100% | -$474,045 | |||||
2024-11-14 | DYN | Rhodes Jason P | Dir | S - Sale | $33.10 | -782 | 847,316 | 0% | -$25,884 | ||||||
2024-11-18 | DYN | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale | $28.20 | -2,735 | 95,833 | -3% | -$77,127 | ||||||
2024-11-18 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $28.20 | -2,856 | 137,519 | -2% | -$80,539 | ||||||
| M | 2024-11-13 | DYN | Kersten Dirk | Dir | S - Sale | $34.14 | -19,732 | 5,786,435 | 0% | -$673,748 | |||||
| M | 2024-10-18 | DYN | Kersten Dirk | Dir | S - Sale | $35.16 | -13,535 | 5,868,468 | 0% | -$475,879 | |||||
| M | 2024-10-16 | DYN | Kersten Dirk | Dir | S - Sale | $35.29 | -36,684 | 5,882,003 | -1% | -$1,294,437 | |||||
| M | 2024-10-01 | DYN | Kersten Dirk | Dir | S - Sale | $35.32 | -29,941 | 5,924,128 | -1% | -$1,057,460 | |||||
| M | 2024-09-27 | DYN | Kersten Dirk | Dir | S - Sale | $35.50 | -30,974 | 5,954,069 | -1% | -$1,099,697 | |||||
| M | 2024-09-25 | DYN | Kersten Dirk | Dir | S - Sale | $35.14 | -3,617 | 5,985,043 | 0% | -$127,102 | |||||
| M | 2024-09-20 | DYN | Kersten Dirk | Dir | S - Sale | $36.07 | -120,242 | 5,988,660 | -2% | -$4,336,893 | |||||
| M | 2024-09-18 | DYN | Kersten Dirk | Dir | S - Sale | $36.15 | -80,293 | 6,108,902 | -1% | -$2,902,720 | |||||
2024-09-18 | DYN | High Susanna Gatti | COO | S - Sale | $34.41 | -8,976 | 131,636 | -6% | -$308,864 | ||||||
2024-09-18 | DYN | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale | $34.55 | -1,390 | 98,568 | -1% | -$48,025 | ||||||
2024-09-18 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $34.55 | -2,339 | 140,375 | -2% | -$80,812 | ||||||
| M | 2024-09-16 | DYN | Kersten Dirk | Dir | S - Sale | $35.10 | -4,592 | 6,189,195 | 0% | -$161,198 | |||||
2024-09-11 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $31.89 | -2,161 | 142,714 | -1% | -$68,914 | ||||||
2024-09-11 | DYN | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale | $31.89 | -1,468 | 99,958 | -1% | -$46,815 | ||||||
2024-09-11 | DYN | High Susanna Gatti | COO | S - Sale | $31.89 | -5,270 | 140,612 | -4% | -$168,060 | ||||||
| D | 2024-09-06 | DYN | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale+OE | $32.15 | -126,074 | 101,426 | -55% | -$4,052,851 | |||||
2024-09-05 | DYN | Kersten Dirk | Dir | S - Sale | $35.03 | -1,577 | 6,193,787 | 0% | -$55,242 | ||||||
2024-09-04 | DYN | Cox John | CEO, Pres | P - Purchase | $33.04 | +32,000 | 37,000 | +640% | +$1,057,216 | ||||||
2024-08-30 | DYN | Kersten Dirk | Dir | S - Sale | $45.59 | -31,300 | 6,195,364 | -1% | -$1,427,063 | ||||||
| M | 2024-08-28 | DYN | Kersten Dirk | Dir | S - Sale | $45.03 | -134,261 | 6,226,664 | -2% | -$6,045,783 | |||||
| M | 2024-08-26 | DYN | Kersten Dirk | Dir | S - Sale | $44.87 | -154,900 | 6,360,925 | -2% | -$6,950,453 | |||||
| M | 2024-08-22 | DYN | Kersten Dirk | Dir | S - Sale | $46.02 | -180,409 | 6,515,825 | -3% | -$8,302,088 | |||||
| M | 2024-08-20 | DYN | Kersten Dirk | Dir | S - Sale | $46.61 | -222,603 | 6,696,234 | -3% | -$10,375,620 | |||||
2024-08-19 | DYN | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale | $45.12 | -2,752 | 111,022 | -2% | -$124,174 | ||||||
2024-08-19 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale | $45.12 | -2,705 | 132,106 | -2% | -$122,054 | ||||||
2024-08-19 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale | $45.12 | -2,321 | 143,222 | -2% | -$104,727 | ||||||
2024-08-19 | DYN | High Susanna Gatti | COO | S - Sale | $45.12 | -2,910 | 145,882 | -2% | -$131,304 | ||||||
2024-08-19 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $45.12 | -2,636 | 144,875 | -2% | -$118,939 | ||||||
| M | 2024-08-16 | DYN | Kersten Dirk | Dir | S - Sale | $45.48 | -248,675 | 6,918,837 | -3% | -$11,310,183 | |||||
| M | 2024-08-14 | DYN | Kersten Dirk | Dir | S - Sale | $44.76 | -281,541 | 7,167,512 | -4% | -$12,601,536 | |||||
| M | 2024-08-12 | DYN | Kersten Dirk | Dir | S - Sale | $42.93 | -212,477 | 7,449,053 | -3% | -$9,121,902 | |||||
| AM | 2024-08-08 | DYN | Kersten Dirk | Dir | S - Sale | $42.85 | -183,834 | 7,661,530 | -2% | -$7,877,091 | |||||
| M | 2024-08-08 | DYN | Kersten Dirk | Dir | S - Sale | $42.85 | -183,834 | 7,661,530 | -2% | -$7,877,091 | |||||
| ADM | 2024-06-21 | DYN | High Susanna Gatti | COO | S - Sale+OE | $35.09 | -40,000 | 148,792 | -21% | -$1,403,668 | |||||
| DM | 2024-06-21 | DYN | High Susanna Gatti | COO | S - Sale+OE | $35.09 | -39,950 | 148,792 | -21% | -$1,401,902 | |||||
| D | 2024-06-12 | DYN | High Susanna Gatti | COO | S - Sale+OE | $33.36 | -40,000 | 148,792 | -21% | -$1,334,201 | |||||
2024-06-11 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $31.34 | -2,136 | 147,511 | -1% | -$66,942 | ||||||
2024-06-11 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale | $31.27 | -2,636 | 145,543 | -2% | -$82,428 | ||||||
| DM | 2024-06-10 | DYN | High Susanna Gatti | COO | S - Sale+OE | $30.30 | -85,270 | 148,792 | -36% | -$2,583,782 | |||||
2024-06-11 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale | $31.34 | -1,823 | 134,811 | -1% | -$57,133 | ||||||
| M | 2024-06-10 | DYN | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale | $30.74 | -2,921 | 113,774 | -3% | -$89,779 | |||||
| D | 2024-05-20 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale+OE | $32.96 | -30,426 | 149,647 | -17% | -$1,002,751 | |||||
2024-05-16 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $28.27 | -2,705 | 149,647 | -2% | -$76,469 | ||||||
2024-05-16 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale | $28.27 | -2,381 | 148,179 | -2% | -$67,310 | ||||||
2024-05-16 | DYN | High Susanna Gatti | COO | S - Sale | $28.27 | -2,738 | 154,062 | -2% | -$77,402 | ||||||
2024-05-16 | DYN | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale | $28.27 | -2,588 | 116,695 | -2% | -$73,162 | ||||||
2024-05-16 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale | $28.27 | -2,774 | 136,634 | -2% | -$78,420 | ||||||
| M | 2024-03-08 | DYN | High Susanna Gatti | COO | S - Sale | $26.59 | -29,491 | 156,800 | -16% | -$784,248 | |||||
| DM | 2024-03-08 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale+OE | $26.11 | -109,601 | 139,408 | -44% | -$2,861,373 | |||||
| M | 2024-03-11 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale | $25.65 | -2,615 | 150,560 | -2% | -$67,082 | |||||
| DM | 2024-03-08 | DYN | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale+OE | $26.19 | -88,924 | 119,283 | -43% | -$2,329,007 | |||||
| DM | 2024-03-08 | DYN | Brumm Joshua T | CEO, Pres | S - Sale+OE | $25.89 | -429,730 | 537,998 | -44% | -$11,125,776 | |||||
2024-03-11 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $25.70 | -2,081 | 152,352 | -1% | -$53,482 | ||||||
2024-03-07 | DYN | Brumm Joshua T | CEO, Pres | S - Sale | $25.85 | -9,086 | 554,385 | -2% | -$234,873 | ||||||
2024-03-07 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $25.85 | -2,373 | 154,433 | -2% | -$61,342 | ||||||
2024-03-07 | DYN | High Susanna Gatti | COO | S - Sale | $25.85 | -1,591 | 186,291 | -1% | -$41,127 | ||||||
2024-03-07 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale | $25.86 | -9,921 | 153,175 | -6% | -$256,585 | ||||||
2024-03-07 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale | $25.85 | -2,434 | 141,184 | -2% | -$62,919 | ||||||
2024-03-07 | DYN | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale | $25.85 | -2,273 | 121,955 | -2% | -$58,757 | ||||||
2024-03-01 | DYN | Rhodes Jason P | Dir | S - Sale | $30.05 | -46,534 | 6,545,479 | -1% | -$1,398,347 | ||||||
2024-03-01 | DYN | Atlas Venture Opportunity Fund I, L.P. | 10% | S - Sale | $30.05 | -46,534 | 2,306,079 | -2% | -$1,398,347 | ||||||
| DM | 2024-02-29 | DYN | Brumm Joshua T | CEO, Pres | S - Sale+OE | $28.96 | -100,000 | 563,471 | -15% | -$2,895,519 | |||||
| DM | 2024-02-29 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale+OE | $28.46 | -28,528 | 143,618 | -17% | -$811,865 | |||||
| DM | 2024-02-29 | DYN | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale+OE | $28.05 | -12,740 | 124,228 | -9% | -$357,296 | |||||
| M | 2024-02-26 | DYN | Rhodes Jason P | Dir | S - Sale | $24.30 | -807,838 | 864,487 | -48% | -$19,626,903 | |||||
| M | 2024-02-26 | DYN | Atlas Venture Fund Xi, L.P. | 10% | S - Sale | $24.30 | -807,838 | 6,562,578 | -11% | -$19,626,903 | |||||
| M | 2024-02-21 | DYN | Rhodes Jason P | Dir | S - Sale | $22.64 | -500,789 | 920,843 | -35% | -$11,339,780 | |||||
| M | 2024-02-21 | DYN | Atlas Venture Fund Xi, L.P. | 10% | S - Sale | $22.64 | -500,789 | 7,273,405 | -6% | -$11,339,780 | |||||
| M | 2024-02-15 | DYN | Rhodes Jason P | Dir | S - Sale | $23.26 | -510,152 | 9,359,331 | -5% | -$11,867,292 | |||||
| M | 2024-02-15 | DYN | Atlas Venture Fund Xi, L.P. | 10% | S - Sale | $23.26 | -510,152 | 6,815,965 | -7% | -$11,867,292 | |||||
2024-02-12 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale | $25.07 | -5,493 | 163,503 | -3% | -$137,710 | ||||||
2024-01-26 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale | $25.00 | -100 | 168,996 | 0% | -$2,500 | ||||||
| D | 2024-01-26 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale+OE | $24.53 | -20,000 | 143,618 | -12% | -$490,510 | |||||
| D | 2024-01-26 | DYN | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale+OE | $24.34 | -13,000 | 124,228 | -9% | -$316,420 | |||||
2024-01-09 | DYN | Kersten Dirk | Dir, 10% | P - Purchase | $17.50 | +1,714,285 | 1,428,571 | -600% | +$29,999,988 | ||||||
| DM | 2024-01-03 | DYN | Brumm Joshua T | CEO, Pres | S - Sale+OE | $18.66 | -269,719 | 584,971 | -32% | -$5,032,915 | |||||
| DM | 2024-01-03 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale+OE | $18.57 | -87,779 | 156,806 | -36% | -$1,629,985 | |||||
| DM | 2024-01-02 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale+OE | $16.59 | -31,900 | 143,618 | -18% | -$529,194 | |||||
| D | 2024-01-03 | DYN | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale+OE | $18.81 | -13,000 | 124,228 | -9% | -$244,530 | |||||
2023-12-14 | DYN | Scalzo Richard William | See Remarks | S - Sale | $12.02 | -2,376 | 124,228 | -2% | -$28,560 | ||||||
2023-12-11 | DYN | Scalzo Richard William | See Remarks | S - Sale | $10.72 | -1,380 | 126,604 | -1% | -$14,794 | ||||||
2023-12-11 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale | $10.72 | -1,245 | 155,518 | -1% | -$13,346 | ||||||
2023-12-11 | DYN | High Susanna Gatti | COO | S - Sale | $10.72 | -1,616 | 187,882 | -1% | -$17,324 | ||||||
| M | 2023-12-11 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale | $10.66 | -2,666 | 169,096 | -2% | -$28,413 | |||||
2023-12-11 | DYN | Brumm Joshua T | See Remarks | S - Sale | $10.72 | -7,585 | 584,971 | -1% | -$81,311 | ||||||
2023-12-11 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $10.72 | -1,467 | 176,585 | -1% | -$15,726 | ||||||
| M | 2023-12-04 | DYN | Scalzo Richard William | See Remarks | S - Sale | $12.01 | -2,553 | 127,984 | -2% | -$30,662 | |||||
2023-11-02 | DYN | High Susanna Gatti | COO | S - Sale | $7.40 | -9,939 | 94,605 | -10% | -$73,549 | ||||||
2023-09-18 | DYN | Scalzo Richard William | See Remarks | S - Sale | $9.41 | -1,290 | 40,795 | -3% | -$12,139 | ||||||
2023-09-18 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale | $9.41 | -1,261 | 60,605 | -2% | -$11,866 | ||||||
2023-09-18 | DYN | High Susanna Gatti | COO | S - Sale | $9.41 | -2,672 | 104,544 | -2% | -$25,144 | ||||||
2023-09-18 | DYN | Brumm Joshua T | See Remarks | S - Sale | $9.41 | -12,032 | 233,679 | -5% | -$113,221 | ||||||
2023-09-18 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $9.41 | -1,436 | 84,334 | -2% | -$13,513 | ||||||
2023-09-12 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale | $10.41 | -1,707 | 89,250 | -2% | -$17,770 | ||||||
2023-09-12 | DYN | Scalzo Richard William | See Remarks | S - Sale | $10.41 | -1,397 | 42,085 | -3% | -$14,543 | ||||||
2023-09-12 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale | $10.41 | -1,266 | 61,866 | -2% | -$13,179 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |